MoonLake Immunotherapeutics

Sonelokimab demonstrated compelling Phase 3 efficacy in hidradenitis suppurativa, with 67% of patients achieving strong disease improvement and 33% reaching complete skin clearance at one year. MoonLake plans to file a BLA with the FDA by September 30 and request Priority Review, signaling confidence in near-term approval.

Despite promising Phase 3 data, MLTX faces stiff competitive pressure, particularly from SKYRIZI in PsA, which could limit sonelokimab's market share. The lack of near-term catalysts beyond the BLA filing and ongoing trial readouts makes the stock a speculative hold rather than a conviction buy.

Merck previously submitted a non-binding acquisition offer valuing MoonLake at over $3 billion, validating the company's late-stage pipeline. With Merck facing Keytruda patent cliff pressure, analysts and retail traders view MLTX as a prime buyout target, with renewed speculation following Merck's acquisition of Terns.

MoonLake's initial rejection of Merck's offer and the absence of confirmed renewed negotiations introduce significant deal uncertainty. MLTX's market cap sits at only $1.5 billion with an enterprise value of roughly $1.2 billion, suggesting the market is discounting the probability of a completed acquisition.

MoonLake holds approximately $298.5 million in cash as of Q1, and recently priced a $200 million public offering to further support pipeline development and commercialization. Analysts estimate the company's cash runway extends into 2027–2028, providing meaningful operational security through key clinical and regulatory milestones.

MLTX is forecast to remain unprofitable through at least 2028, with projected losses of $268–$293 million annually and a future return on equity of nearly -200%. The recent $200 million share offering signals ongoing cash burn pressure and dilutes existing shareholders, raising concerns about long-term capital efficiency.